Thermo Fisher ScientificTMO
TMO
About: Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
Employees: 125,000
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
14% more funds holding in top 10
Funds holding in top 10: 72 [Q4 2024] → 82 (+10) [Q1 2025]
2% more repeat investments, than reductions
Existing positions increased: 1,010 | Existing positions reduced: 986
0.9% less ownership
Funds ownership: 88.22% [Q4 2024] → 87.32% (-0.9%) [Q1 2025]
5% less first-time investments, than exits
New positions opened: 148 | Existing positions closed: 156
2% less funds holding
Funds holding: 2,570 [Q4 2024] → 2,509 (-61) [Q1 2025]
8% less capital invested
Capital invested by funds: $177B [Q4 2024] → $164B (-$13.5B) [Q1 2025]
11% less call options, than puts
Call options by funds: $961M | Put options by funds: $1.08B
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$470
17%
upside
Avg. target
$550
37%
upside
High target
$637
58%
upside
9 analyst ratings
7 positive
78%
2 neutral
22%
0 negative
0%
Argus Research David Toung | 17%upside $470 | Buy Maintained | 29 Apr 2025 |
Scotiabank Sung Ji Nam | 50%upside $605 | Sector Perform Maintained | 25 Apr 2025 |
RBC Capital Conor McNamara | 58%upside $637 | Outperform Maintained | 24 Apr 2025 |
UBS Dan Leonard | 24%upside $500 | Buy Maintained | 24 Apr 2025 |
Stifel Daniel Arias | 54%upside $620 | Buy Maintained | 24 Apr 2025 |
Financial journalist opinion
Based on 18 articles about TMO published over the past 30 days
Negative
PYMNTS
1 day ago
Report: Biotech Research Firm Thermo Fisher Considers Selling Diagnostics Business
Biotechnology research firm Thermo Fisher Scientific is reportedly looking to sell part of its diagnostics business amid industrywide concerns about federal cutbacks in spending on research.
Neutral
Zacks Investment Research
1 day ago
Thermo Fisher Stock Hurt by Macroeconomic Woes, Tough Competition
TMO grapples with macro pressures, rising expenses and fierce competition, but bets on acquisitions to fuel recovery.
Neutral
Business Wire
1 day ago
Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms
MUNICH--(BUSINESS WIRE)--Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to provide a fully integrated mRNA solution to biopharmaceutical developers. The collaboration brings together Ethris' comprehensive mRNA technology platforms, including its proprietary Stabilized Non-Immunogenic mRNA (SNIM® RNA), minimal UTR and mRNA ma.
Neutral
Reuters
2 days ago
Thermo Fisher plans to sell parts of diagnostics unit for $4 billion, FT reports
Thermo Fisher Scientific plans to sell its diagnostics unit for about $4 billion in an attempt to offload some of its low-growth assets, the Financial Times reported on Thursday, citing people familiar with the matter.
Neutral
Zacks Investment Research
1 week ago
TMO Launches Next-Generation Mass Spectrometers: Stock to Gain?
Thermo Fisher debuts two advanced MSs, Orbitrap Astral Zoom and Orbitrap Excedion Pro, to accelerate precision medicine and drug discovery breakthroughs.
Neutral
Business Wire
1 week ago
Thermo Fisher Scientific Unveils Next-generation Mass Spectrometers at ASMS 2025 to Revolutionize Biopharma Applications and Omics Research
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the launch of the Thermo Scientific™ Orbitrap™ Astral™ Zoom mass spectrometer (MS) and the Thermo Scientific™ Orbitrap™ Excedion™ Pro mass spectrometer (MS) to help push the boundaries of scientific discovery. Delivering unrivaled analytical performance and speed, the instruments are designed to uncover complex biological processes that could lead to advancements in p.
Positive
Seeking Alpha
1 week ago
Thermo Fisher: With A 30% Price Drop, Trump Legislation, And High Capex, Is It Undervalued?
The neutral DCF model implemented in this article suggests that Thermo Fisher is undervalued by 29.24%. Thermo Fisher has invested, on average, 16.51% of its revenues in capex between 2019 and 2024. Due to the significant investment in capex, Thermo Fisher's revenues have increased at a 12.95% CAGR between 2019 and 2024.
Neutral
Seeking Alpha
1 week ago
Thermo Fisher Is Strengthening Its Long-Term Advantage
Thermo Fisher's 2025 headwinds from tariffs and US research funding cuts are real but temporary, not reflective of structural weakness in its fundamentals. The company is mitigating trade impacts by investing $2B in US manufacturing, leveraging diversification and innovation, and expects headwinds to peak this year. Biopharma growth, strategic acquisitions, and rapid product innovation position TMO for long-term outperformance versus less diversified peers.
Positive
Seeking Alpha
2 weeks ago
So Cheap It's Silly - 2 Dividend Stocks I'd Buy Twice If I Could
Market extremes often drive flawed narratives. Many investors get spooked by sell-offs or seduced by overvaluations, when real opportunity hides in discomfort. While today's market isn't euphoric, it's not cheap either. Risks remain, especially if growth stumbles. Yet long-term valuations may have structurally shifted. That's why I'm laser-focused on deep-value names. In this article, I highlight two standout stocks with unique long-term potential at compelling valuations.
Positive
Zacks Investment Research
2 weeks ago
Thermo Fisher Launches New Spectral Flow Cytometer: Stock to Gain?
TMO unveils spectral-enabled Attune Xenith Flow Cytometer to streamline workflows and boost research accuracy.
Charts implemented using Lightweight Charts™